U.S. Markets closed

The Zacks Analyst Blog Highlights: iShares Residential Real Estate Capped ETF, First Trust Amex Biotechnology Index Fund, SPDR S&P Biotech ETF, PowerShares Dynamic Semiconductors and SPDR S&P Semiconductor ETF

Zacks Equity Research

For Immediate Release
Chicago, IL – July 07, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the iShares Residential Real Estate Capped ETF (REZ-Free Report), First Trust Amex Biotechnology Index Fund (FBT-Free Report), SPDR S&P Biotech ETF (XBI-Free Report), PowerShares Dynamic Semiconductors (PSI-Free Report) and SPDR S&P Semiconductor ETF (XSD-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

American ETFs Making Fireworks
Despite broad retail investor disdain for the market, U.S. stocks had another solid start to the year. In fact, the S&P 500 is up over 7% YTD through the first six month months of 2014, putting the benchmark on pace for another double digit return year.

Yet while this broad market gain is definitely solid, it was easily trounced by a few sectors which more than doubled this seven percent performance in the first six months of the year. several segments actually put up gains that exceeded triple the S&P 500’s return in the time frame, showing that even though it may have been rocky, gains were definitely there for the taking in certain segments (also see 5 ETFs Up At Least 10% in the First Half of 2014).

Below, we discuss a few sector ETFs that have put up gains of at least 20% so far in 2014. All of these segments also focus exclusively on American equities, so they should definitely be worth a closer look by those seeking a more home-grown tilt to their portfolios following the Fourth of July Holiday:

Real Estate

Thanks to low interest rates, investors continued to pile into real estate across the country. And though home price gains have slowed lately, interest in this space is still quite high especially for yield focused investors.

One pick that has done exceptionally well in this market is the iShares Residential Real Estate Capped ETF (REZ-Free Report). This ETF has added close to 21% YTD, while it pays a 30-Day SEC yield of about 3.5%, making it a decent income choice as well (also see 4 ETFs Riding High in Q2).

Top holdings in this fund include Public Storage, Equity Residential, and Health Care REIT, though it is worth noting only 36 companies comprise the entire basket of the ETF. Still, this concentrated approach hasn’t stopped REZ from putting up very solid gains, though investors should note that the product currently has a Zacks ETF Rank #4 (Sell) so some longer term pain might be ahead.


Biotechnology was a very hot sector to start the year, though worries over high growth stocks really derailed the story in this space. However, a surge in M&A activity rekindled interest here and made many of the top funds in this segment all-star performers once more.

In particular, the First Trust Amex Biotechnology Index Fund (FBT-Free Report) and the SPDR S&P Biotech ETF (XBI-Free Report) managed to edge out the competition. Both of these funds put up gains of at least 21% YTD, nearly tripling SPY for the time frame (read The Guide to Surging Biotech ETFs).

Both of these products were helped by their focus on small and micro cap securities, as opposed to others in the segment. The surge in M&A deals and rumors really helped these pint-sized companies, making FBT and XBI prime beneficiaries.
Although the tech sector saw some rockiness, the semiconductor space was a surprise winner to start the year. Strength in many of the big names in this space was a prime reason for the outperformance, while strong Zacks Industry Ranks for many segments here didn’t hurt matters either.
Several funds really stood out here, including (PSI-Free Report) and (XSD-Free Report). All three saw gains of at least 21% to start the year, though XSD did managed to edge out its competitors this round with a nearly 24% performance (see all the Technology ETFs here).  
XSD’s outperformance can at least partially be attributed to its focus on small and mid caps with its equal weight methodology. This tilt towards higher beta names came in handy in the past few months, and with a strong industry rank in this corner of the market, more fireworks could come to this space to close out the year as well.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on QEP - FREE
Get the full Report on ECA - FREE
Get the full Report on UPL - FREE
Get the full Report on VZ - FREE
Get the full Report on INTC - FREE
Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on REZ

Read the analyst report on FBT

Read the analyst report on XBI

Read the analyst report on PSI

Read the analyst report on XSD

Zacks Investment Research